State Street’s Kyntra Bio KYNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$153K Hold
20,284
﹤0.01% 3891
2026
Q1
$138K Hold
20,284
﹤0.01% 3971
2025
Q4
$178K Hold
20,284
﹤0.01% 3921
2025
Q3
$248K Buy
20,284
+6,565
+48% +$61.7K ﹤0.01% 3846
2025
Q2
$72.7K Sell
13,719
-3
-0% -$22 ﹤0.01% 4030
2025
Q1
$106K Hold
13,722
﹤0.01% 3964
2024
Q4
$182K Buy
13,722
+35
+0.3% +$325 ﹤0.01% 3872
2024
Q3
$137K Sell
13,687
-1,908
-12% -$28.8K ﹤0.01% 3914
2024
Q2
$348K Sell
15,595
-70,920
-82% -$2.19M ﹤0.01% 3651
2024
Q1
$5.08M Buy
86,515
+14,088
+19% +$607K ﹤0.01% 2918
2023
Q4
$1.6M Buy
72,427
+4,192
+6% +$63.2K ﹤0.01% 3371
2023
Q3
$1.47M Sell
68,235
-132,333
-66% -$5.2M ﹤0.01% 3434
2023
Q2
$13.5M Buy
200,568
+37,521
+23% +$15.5M ﹤0.01% 2478
2023
Q1
$76.1M Sell
163,047
-7,552
-4% -$4M ﹤0.01% 1370
2022
Q4
$68.3M Buy
170,599
+1,621
+1% +$621K ﹤0.01% 1424
2022
Q3
$55M Sell
168,978
-15,347
-8% -$4.94M ﹤0.01% 1529
2022
Q2
$48.7M Sell
184,325
-12,786
-6% -$3.27M ﹤0.01% 1657
2022
Q1
$59.2M Buy
197,111
+16,833
+9% +$5.87M ﹤0.01% 1650
2021
Q4
$63.5M Sell
180,278
-80,245
-31% -$25M ﹤0.01% 1648
2021
Q3
$66.6M Buy
260,523
+123,674
+90% +$43.8M ﹤0.01% 1594
2021
Q2
$91.1M Buy
136,849
+16,009
+13% +$9.22M ﹤0.01% 1366
2021
Q1
$105M Sell
120,840
-6,506
-5% -$6.93M 0.01% 1198
2020
Q4
$118M Buy
127,346
+15,222
+14% +$16M 0.01% 1022
2020
Q3
$115M Sell
112,124
-12,238
-10% -$13.2M 0.01% 892
2020
Q2
$126M Buy
124,362
+17,880
+17% +$16.6M 0.01% 829
2020
Q1
$92.5M Buy
106,482
+998
+0.9% +$992K 0.01% 899
2019
Q4
$113M Sell
105,484
-8,627
-8% -$8.81M 0.01% 973
2019
Q3
$105M Sell
114,111
-7,338
-6% -$8.06M 0.01% 974
2019
Q2
$137M Buy
121,449
+11,433
+10% +$12.5M 0.01% 853
2019
Q1
$149M Buy
110,016
+3,570
+3% +$4.84M 0.01% 780
2018
Q4
$123M Buy
106,446
+1,942
+2% +$2.18M 0.01% 801
2018
Q3
$159M Buy
104,504
+5,503
+6% +$8.48M 0.01% 805
2018
Q2
$155M Sell
99,001
-9,848
-9% -$12.8M 0.01% 793
2018
Q1
$126M Buy
108,849
+6,763
+7% +$8.91M 0.01% 881
2017
Q4
$121M Buy
102,086
+25,897
+34% +$32.5M 0.01% 923
2017
Q3
$102M Buy
76,189
+5,654
+8% +$5.96M 0.01% 969
2017
Q2
$57M Buy
70,535
+9,956
+16% +$6.94M 0.01% 1285
2017
Q1
$37.3M Buy
60,579
+6,033
+11% +$3.67M ﹤0.01% 1499
2016
Q4
$29.2M Buy
54,546
+2,497
+5% +$1.25M ﹤0.01% 1618
2016
Q3
$26.9M Sell
52,049
-1,113
-2% -$524K ﹤0.01% 1569
2016
Q2
$21.8M Sell
53,162
-70
-0.1% -$32.1K ﹤0.01% 1694
2016
Q1
$28.3M Buy
53,232
+6,974
+15% +$3.48M ﹤0.01% 1492
2015
Q4
$35.2M Buy
46,258
+16,586
+56% +$11M ﹤0.01% 1358
2015
Q3
$16.3M Buy
29,672
+4,036
+16% +$2.45M ﹤0.01% 1889
2015
Q2
$15.1M Buy
25,636
+21,467
+515% +$12.5M ﹤0.01% 2028
2015
Q1
$3.27M Buy
4,169
+1,159
+39% +$899K ﹤0.01% 2801
2014
Q4
$2.06M Buy
+3,010
New +$1.94M ﹤0.01% 3029

Other funds holding KYNB

State Street's KYNB Position: Q2 2026 in Review

State Street held its Kyntra Bio (KYNB) position steady in Q2 2026 at 20,284 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #3891.

State Street first reported a position in KYNB in Q4 2014 and has held it in 47 quarters since. The position peaked at $159M in Q3 2018. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • State Street held 20,284 shares of Kyntra Bio worth $153K as of Q2 2026.
  • State Street left its Kyntra Bio share count unchanged in Q2 2026.
  • Kyntra Bio made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3891 holding.
  • State Street first reported a position in Kyntra Bio in Q4 2014 and has held it in 47 quarters since.
  • State Street's Kyntra Bio position peaked at $159M in Q3 2018.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.